# Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Canonical URL: https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-confe-b815d20d Ticker: IRWD Company: Ironwood Pharmaceuticals Source: Ironwood Pharmaceuticals Published: 2026-05-28 20:05 EST Original Source URL: https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference/default.aspx ## Summary Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 th at 11:05 a.m. ET. A live webcast of Ironwood’s fireside chat will be accessible through the Investors Media section of the company’s website at www.ironwoodpharma.com . A replay of the webcast will be available on Ironwood’s website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with ## Article Body Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 th at 11:05 a.m. ET. A live webcast of Ironwood’s fireside chat will be accessible through the Investors & Media section of the company’s website at www.ironwoodpharma.com . A replay of the webcast will be available on Ironwood’s website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn . Source: Ironwood Pharmaceuticals, Inc. ## Recent Company News - 2026-07-14 11:30 EST — [Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients](https://biopharmsignal.com/news/IRWD/ironwood-appoints-dr-jeffrey-silber-chief-medical-officer-and-head-of-research-a-b6d13a27) — Source: Ironwood Pharmaceuticals - 2026-05-28 20:05 EST — [Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-confe-b815d20d) — Source: Ironwood Pharmaceuticals - 2026-05-27 14:00 EST — [FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)](https://biopharmsignal.com/news/IRWD/fda-approves-use-of-linzessr-linaclotide-in-pediatric-patients-two-years-of-age-and-older-with-functional-constipation-fc) — Source: Ironwood Pharmaceuticals - 2026-05-07 11:05 EST — [Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance](https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-reports-strong-first-quarter-2026-results-with-97-year-over-year-linzess-u-s-net-sales-growth-maintains-full-year-2026-financial-guidance) — Source: Ironwood Pharmaceuticals - 2026-05-04 11:05 EST — [Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)](https://biopharmsignal.com/news/IRWD/ironwood-survey-findings-at-ddw-2026-underscore-need-for-therapies-that-address-multiple-dimensions-of-total-parenteral-nutrition-tpn-burden-in-short-bowel-syndrome-sbs) — Source: Ironwood Pharmaceuticals ## Related News - 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8) - 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05) - 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004) - 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7) - 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)